In this Healio Video Perspective from the ASRS meeting, Dilsher Dhoot, MD, of California Retina Consultants discusses interim safety and efficacy results for OTX-TKI for the treatment of nonproliferative diabetic retinopathy.
According to Dhoot, patients with moderately severe to severe nonproliferative diabetic retinopathy were randomly assigned 2:1 to receive OTX-TKI (axitinib intravitreal implant, Ocular Therapeutix) or sham and then followed for 52 weeks. The study’s primary endpoint was safety and tolerability, while secondary endpoints included change in Diabetic Retinopathy